OakChart

Evommune Inc

EVMNHealthcare·Biotechnology·USA·Small·NYSE·Nov 11 • 3:59 PM ET

8.62+0.78 (9.95%)
2026-11-12 05:23 CET
Market cap
312.84 USD m
Revenue, TTM
10.00 USD m
Net income, TTM
-94.67 USD m
Free cash flow, TTM
-74.65 USD m
EPS diluted, TTM
-2.83
P/E
-
Compare

Price

EVMN against its 20, 50 and 200-day averages
2050200miss
5.0010.0015.0020.0025.005.3M10.6MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26EVMNclose 8.6220-day 6.1250-day 7.74200-day 17.288.6252w low

74.0% under the 52-week high of 33.20 on 10 Feb 2026. 52-week low 4.94 on 23 Oct 2026. Last 15 sessions, 80.8% high to low

Volume 1.82× normal · the line is the 50-bar volume average

Profile

EVMN
52-week range, 13% of the way up
4.9433.20

Evommune, Inc. is a clinical-stage biotechnology company. It engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pena, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Palo Alto, CA.

IndexRUT
Employees48
IPONov 06, 2025
Beta1.25
ATR, 14d0.70
Rel volume1.82
Short float15.26%
Insider own38.83%
Inst own69.68%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap312.84M
Enterprise Value120.68M
Income-94.67M
Sales10.00M
Book/sh7.65
Cash/sh5.53
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees48
IPONov 06, 2025

Ratios

P/E-
Forward P/E-
PEG-
P/S31.28
P/B1.13
P/C1.56
P/FCF-
EV/EBITDA-
EV/Sales12.07
Quick Ratio11.68
Current Ratio11.68
Debt/Eq0.03
LT Debt/Eq0.02
Option/ShortYes / Yes

Earnings

EPS (ttm)-2.83
EPS next Y-3.51
EPS next Q-0.83
EPS this Y68.99%
EPS next Y-0.95%
EPS next 5Y33.74%
EPS past 3/5Y-38.91% -
Sales past 3/5Y61.25% -
EPS Y/Y TTM-
Sales Y/Y TTM-
EPS Q/Q-97.87%
Sales Q/Q-
EarningsAug 06 AMC
EPS/Sales Surpr.-33.94% -100.00%

Ownership

Insider Own38.83%
Insider Trans-0.63%
Inst Own69.68%
Inst Trans-3.97%
ROA-47.55%
ROE-178.03%
ROIC-33.28%
Gross Margin84.62%
Oper. Margin-1018.93%
Profit Margin-946.68%
SMA2040.75%
SMA5011.33%
SMA200-50.12%
Trades-

Technical

Shs Outstand36.28M
Shs Float22.20M
Short Float15.26%
Short Ratio4.30
Short Interest3.39M
52W High33.20 -74.04%
52W Low4.94 74.49%
Volatility12.66% 10.60%
ATR (14)0.70
RSI (14)68.38
Beta1.25
Rel Volume1.82
Avg Volume787.85K
Volume1,432,913

Performance

Perf Week42.72%
Perf Month46.60%
Perf Quarter-38.73%
Perf Half Y-62.99%
Perf YTD-49.65%
Perf Year-55.73%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.54
Target Price22.80
Prev Close7.84
Price8.62
Change %9.95%

Analyst ratings

latest 10 of 15
DateActionAnalystRating changeTargetImplied
Oct 20, 2026ResumedMMorgan StanleyOverweight$26+201.6%
Oct 12, 2026InitiatedUUBSNeutral$8-7.2%
Aug 26, 2026InitiatedNNeedhamBuy$28+224.8%
Jun 30, 2026DowngradeHH.C. WainwrightBuy → Neutral
Jun 29, 2026DowngradeWWilliam BlairOutperform → Mkt Perform
May 01, 2026InitiatedSStifelBuy$54+526.5%
Apr 07, 2026ResumedOOppenheimerOutperform$50+480.0%
Jan 22, 2026InitiatedOOppenheimerOutperform$42+387.2%
Jan 08, 2026InitiatedRRaymond JamesStrong Buy$40+364.0%
Jan 06, 2026InitiatedHH.C. WainwrightBuy$35+306.0%

Peers

Mkt cap
TickerCompanyMkt cap
ACRSAclaris Therapeutics Inc688.38M
ATTOAttovia Therapeutics Inc764.77M
JSPRJasper Therapeutics Inc16.37M
UPBUpstream Bio Inc175.27M
ZURAZura Bio Ltd137.75M
ALMSAlumis Inc883.74M
AVTXAvalo Therapeutics Inc492.07M
ORKAOruka Therapeutics Inc7.27B
CNTBConnect Biopharma Holdings Ltd43.38M
JBIOJade Biosciences Inc1.05B

Insider trading

latest 14 of 22
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Carver KyleChief Financial OfficerJul 08 '26Buy13.261,00013,26060,335Jul 10 07:59 PM
KIRSCH ARTHUR SDirectorJul 07 '26Buy13.3010,000133,00010,000Jul 08 08:00 PM
Drew Janice SuzannChief of Dev. OperationsJun 22 '26Option Exercise3.1520,00063,06387,794Jun 24 08:00 PM
Drew Janice SuzannChief of Dev. OperationsJun 22 '26Sale22.6320,000452,60067,794Jun 24 08:00 PM
Patel Jeegar PravinkumarChief Scientific OfficerJun 22 '26Option Exercise3.841,4885,71447,891Jun 24 08:00 PM
Patel Jeegar PravinkumarChief Scientific OfficerJun 22 '26Sale22.501,48833,48046,403Jun 24 08:00 PM
Pena Luis C.President & CEOJun 22 '26Sale22.717,438168,917630,458Jun 24 07:59 PM
JANICE DREWOfficerJun 22 '26Proposed Sale21.3620,000427,200Jun 22 04:45 PM
Cohen David EDirectorJun 02 '26Sale20.336,056123,09417,609Jun 03 08:03 PM
Patel Jeegar PravinkumarChief Scientific OfficerJun 01 '26Option Exercise3.8413,51251,88663,090Jun 03 08:02 PM
Patel Jeegar PravinkumarChief Scientific OfficerJun 01 '26Sale22.7416,687379,46246,403Jun 03 08:02 PM
Pena Luis C.President & CEOJun 01 '26Sale22.7416,787381,736637,896Jun 03 08:02 PM
DAVID COHENDirectorJun 02 '26Proposed Sale22.179,258205,250Jun 02 04:37 PM
Moss Gregory S.Chief Business & Legal OfficerMay 28 '26Option Exercise1.7114,22324,32175,058Jun 01 08:00 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
SBIOALPS Medical Breakthroughs ETFAUM: 192.65M
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M

News

latest 14 of 82

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-06-0.890-0.665-0.8910.001.3310
2026Q12026-05-07-0.640-0.813-0.6440.000.7210
2025Q42026-03-05-1.430-0.817-0.8971.080.007
2025Q32025-12-11-8.070-6.081-0.39610.003.334
2025Q22025-09-03-4.770--0.4510.00--
2026Q3---0.834--0.0012
2026Q4---0.941--0.0012
2027Q1---0.927--0.005
2027Q2---0.949--0.005
2027Q3---1.037--0.005
2027Q4---1.025--0.005
2028Q1---0.632---1
2028Q2---0.627---1
2028Q3---0.655---1
2028Q4---0.647---1

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2025FY-11.220-4.748-11.22013.0013.00
2026FY--3.479--0.00
2027FY--3.512--0.22
2028FY--3.265--0.33
2029FY--4.202--3.00
2030FY--4.356--23.15

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-097010.000.000.00
2026Q3S2026-09-096010.000.000.00
2026Q3S2026-09-046020.000.000.00
2026Q3S2026-08-226010.500.003.00
2026Q3S2026-08-076020.500.003.00
2026Q3S2026-08-066020.500.003.00
2026Q3S2026-06-266020.500.003.00
2026Q3S2026-06-086013.830.0020.00
2026Q3S2026-05-086013.890.0020.00
2026Q3S2026-04-166004.110.0020.00
2026Q3S2026-03-095004.930.0020.00
2026Q3S2026-03-064001.170.004.67
2026Q3S2025-12-123000.000.000.00
2026Q3S2025-11-283000.000.000.00

Estimate history

EPS, annual-1.132-2.271-2.185-2.8287
Period202320242025TTM
EPS, quarterly-0.093-0.91-0.505-0.484-0.451-0.396-0.897-0.644-0.892
PeriodQ1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual571310
Period202320242025TTM
Sales, quarterly7003010000
PeriodQ1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual30.07830.07831.52436.282
Period202320242025MRQ
Shares, quarterly30.07830.07831.52430.07830.07831.52431.52436.01836.282
PeriodQ1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY
Total Revenue10.0013.007.005.00
Cost of Goods Sold Incl. D&A1.541.391.291.00
Gross Profit8.4611.615.714.00
Selling, General and Administrative Excl. Other110.3692.6875.7341.85
Research and Development83.7774.0464.2432.00
Other Operating Expense0.000.000.000.00
Operating Income-101.89-81.07-70.01-37.85
Interest Expense-0.010.030.06
Unusual Expense0.00-8.930.000.00
Net Income Before Taxes-94.67-68.87-66.81-34.05
Income Taxes0.000.000.000.00
Consolidated Net Income-94.67-68.87-66.81-34.05
Net Income From Continuing Operations-94.67-68.87-66.81-34.05
Net Income-94.67-68.87-68.31-34.05
EPS (Recurring)-2.62-2.38-2.27-1.13
EPS (Basic, Before Extraordinaries)-2.83-2.18-2.27-1.13
EPS (Diluted)-2.83-2.18-2.27-1.13
EBITDA-100.36-79.68-68.73-36.85
Non-Operating Income (Expense)7.223.283.243.85
Other After Tax Adjustments0.000.000.000.00
Stock Option Compensation Expense12.815.861.721.48
Price To Sales Ratio48.0241.51--
Gross Margin84.6289.3281.6180.00
Operating Margin-1,018.93-623.62-1,000.19-757.00
Net Margin-946.68-529.77-975.83-681.06
Shares Outstanding36.2831.5230.0830.08
Market Capitalization312.84312.84552.30-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q32024Q2
Total Revenue0.000.000.0010.000.003.000.000.00
Cost of Goods Sold Incl. D&A0.550.350.330.310.380.380.330.33
Gross Profit-0.55-0.35-0.339.69-0.382.62-0.33-0.33
Selling, General and Administrative Excl. Other34.3423.6129.3923.0222.6217.6616.1927.96
Research and Development26.4117.3220.4019.6419.6414.3613.2925.18
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-34.90-23.95-29.72-13.33-22.99-15.03-16.52-28.29
Interest Expense----0.000.000.010.01
Unusual Expense0.000.000.000.00-9.050.120.000.00
Net Income Before Taxes-32.25-21.67-28.27-12.47-13.56-14.56-15.92-27.38
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-32.25-21.67-28.27-12.47-13.56-14.56-15.92-27.38
Net Income From Continuing Operations-32.25-21.67-28.27-12.47-13.56-14.56-15.92-27.38
Net Income-32.25-21.67-28.27-12.47-13.56-14.56-15.92-27.38
EPS (Recurring)-0.89-0.64-0.90-0.40-0.66-0.48-0.50-0.91
EPS (Basic, Before Extraordinaries)-0.89-0.64-0.90-0.40-0.45-0.48-0.50-0.91
EPS (Diluted)-0.89-0.64-0.90-0.40-0.45-0.48-0.50-0.91
EBITDA-34.34-23.61-29.39-13.02-22.62-14.65-16.19-27.96
Non-Operating Income (Expense)2.652.281.440.850.380.600.610.92
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense4.603.454.200.560.560.540.400.41
Price To Sales Ratio48.0277.4141.51-----
Gross Margin---96.89-87.43--
Operating Margin----133.28--501.07--
Net Margin----124.75--485.23--
Shares Outstanding36.2836.0231.5231.5230.0830.0831.5230.08
Market Capitalization312.84828.06539.69552.30----

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY
Cash & Short Term Investments149.2072.0479.08
Short Term Receivables0.000.000.00
Inventories0.000.000.00
Other Current Assets4.281.950.95
Total Current Assets153.4873.9980.03
Net Property, Plant & Equipment2.461.801.97
Total Investments and Advances68.900.210.21
Other Assets0.100.060.04
Total Assets224.9576.0682.25
Short Term Debt Incl. Current Port. of LT Debt0.591.020.77
Accounts Payable7.768.261.76
Other Current Liabilities9.5618.704.33
Total Current Liabilities17.9127.986.86
Long Term Debt1.47192.29149.86
Provision for Risks Charges0.000.000.00
Other Liabilities0.000.023.25
Total Liabilities19.38220.29159.96
Non-Equity Reserves0.000.000.00
Preferred Stock - Carrying Value0.000.000.00
Common Equity205.57-144.24-77.71
Total Shareholders Equity205.57-144.24-77.71
Accumulated Minority Interest0.000.000.00
Total Equity205.57-144.24-77.71
Total Liabilities & Stockholders Equity224.9576.0682.25
Book Value Per Share6.52-4.80-2.58
Tangible Book Value Per Share6.52-4.80-2.58
Full-Time Employees48--
Price to Book Ratio1.13-3.02-
Return on Assets-45.76-84.40-
Return on Equity-224.59--
Return on Invested Capital-33.26-139.02-47.20
Quick Ratio8.572.6411.67
Current Ratio8.572.6411.67

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY
Net Income-94.67-68.87-66.81-34.05
Depreciation1.541.391.291.00
Other Funds (Non Cash)10.16-4.84-0.10-0.26
Funds from Operations-82.97-72.32-65.62-33.31
Extraordinary Item0.000.000.000.00
Changes in Working Capital8.81-4.127.423.34
Cash from Operating Activities-74.15-76.44-58.20-29.97
Capital Expenditures-0.50-0.23-0.09-0.12
Net Assets From Acquisitions0.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.00
Purchase or Sale of Investments-200.37-115.07-3.90-48.31
Purchase of Investments-325.59-199.17-90.25-91.31
Sale Or Maturity of Investments125.2284.1086.3543.00
Other Uses0.000.000.000.00
Other Sources0.000.000.000.00
Cash from Investing Activities-200.87-115.31-3.99-48.43
Cash Dividends Paid0.000.000.000.00
Change in Capital Stock275.00222.3649.8463.98
Repurchase of Common Pref Stock0.000.000.000.00
Sale of Common Pref Stock275.00222.3649.8463.98
Proceedsfrom Stock Options274.27222.3549.8363.98
Issuance or Reduction of Debt, Net-0.60-0.370.000.00
Change in Long Term Debt-0.60-0.370.000.00
Issuance of Long Term Debt0.000.000.000.00
Reduction of Long Term Debt-0.60-0.370.000.00
Net Financing Active Other Cash Flow-0.49-1.220.000.00
Other Financing Activities Uses-0.49-1.220.000.00
Cash from Financing Activities274.22220.7649.4263.75
Net Change in Cash-0.8129.02-12.77-14.65
Free Cash Flow-74.65-76.68-58.28-30.09
Preferred Dividends (Cash Flow)-0.00-0.00
Deferred Taxes & Investment Tax Credit-0.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments200.79211.46149.2076.0686.8048.41
Short Term Receivables1.500.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets1.954.394.284.788.105.91
Total Current Assets204.25215.85153.4880.8494.8954.33
Net Property, Plant & Equipment9.229.572.461.131.051.42
Total Investments and Advances88.4296.9668.901.410.210.21
Other Assets0.070.070.101.160.060.06
Total Assets301.95322.45224.9584.5496.2156.02
Short Term Debt Incl. Current Port. of LT Debt1.751.820.590.500.470.74
Accounts Payable5.044.047.763.583.677.57
Other Current Liabilities10.694.749.566.345.9513.72
Total Current Liabilities17.4910.6017.9110.4210.0922.04
Long Term Debt6.877.301.47257.26257.35192.21
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.01
Total Liabilities24.3617.9019.38267.68267.44214.25
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity277.59304.56205.57-183.14-171.23-158.24
Total Shareholders Equity277.59304.56205.57-183.14-171.23-158.24
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity277.59304.56205.57-183.14-171.23-158.24
Total Liabilities & Stockholders Equity301.95322.45224.9584.5496.2156.02
Book Value Per Share7.658.466.52-5.81-5.69-5.26
Tangible Book Value Per Share7.658.466.52-5.81-5.69-5.26
Full-Time Employees--48--45
Price to Book Ratio1.133.53-2.95-3.02--
Return on Assets-47.55-40.15----
Return on Equity-178.03-103.87----
Return on Invested Capital-11.34-6.95-13.66-16.83-15.75-42.85
Quick Ratio11.6820.368.577.769.402.46
Current Ratio11.6820.368.577.769.402.46

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-32.25-21.67-28.27-12.47-13.56-14.56
Depreciation0.550.350.330.310.380.38
Other Funds (Non Cash)3.842.663.610.05-8.740.24
Funds from Operations-27.85-18.66-24.34-12.12-21.93-13.94
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital7.54-8.847.642.48-4.27-9.96
Cash from Operating Activities-20.32-27.50-16.70-9.63-26.21-23.90
Capital Expenditures-0.18-0.08-0.10-0.130.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments31.48-85.28-122.80-23.7718.0013.50
Purchase of Investments-17.64-108.78-160.40-38.770.000.00
Sale Or Maturity of Investments49.1223.5037.6015.0018.0013.50
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities31.29-85.36-122.90-23.9118.0013.50
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.67117.20158.00-0.8765.230.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.67117.20158.00-0.8765.230.00
Proceedsfrom Stock Options-0.06117.20158.00-0.8765.230.00
Issuance or Reduction of Debt, Net-0.14-0.090.07-0.450.000.00
Change in Long Term Debt-0.14-0.090.07-0.450.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-0.14-0.090.07-0.450.000.00
Net Financing Active Other Cash Flow0.000.00-1.220.74-0.740.00
Other Financing Activities Uses0.000.00-1.220.74-0.740.00
Cash from Financing Activities0.53117.11156.85-0.2764.34-0.15
Net Change in Cash11.514.2517.25-33.8156.13-10.55
Free Cash Flow-20.50-27.59-16.80-9.77-26.21-23.90

Revenue breakdown

Pharmaceutical Preparations2024: 7.00M 2025: 13.00M
United States2024: 7.00M 2025: 13.00M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3015.26%3.4M22.2M784.76K
2026-10-1515.91%3.5M22.2M681.72K
2026-09-3013.83%2.9M20.9M686.46K
2026-09-1513.76%2.9M20.9M854.25K
2026-08-3120.87%4.4M20.9M783.12K
2026-08-1422.60%4.7M20.8M799.44K
2026-07-3122.48%4.5M19.9M776.63K
2026-07-1520.85%4.0M19.3M732.46K
2026-06-3024.79%4.8M19.3M602.49K
2026-06-1522.16%4.3M19.3M372.19K
2026-05-2920.63%4.0M19.3M340.16K
2026-05-1516.11%3.1M19.2M343.08K
2026-04-3016.10%3.2M20.2M600.72K
2026-04-1528.17%3.5M12.3M622.50K
2026-03-3126.94%3.3M12.3M635.11K
2026-03-1324.95%3.1M12.3M613.95K
2026-02-2728.15%3.0M10.8M586.05K
2026-02-1326.32%2.8M10.8M529.16K
2026-01-3014.14%2.5M17.8M271.12K
2026-01-1510.73%1.9M17.8M256.41K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.504.007.800.0016.7050.000.000.983-0.0150.001
call5.001.505.300.508.1344010.000.963-0.0140.001
call7.500.651.951.192.6121,02563.000.748-0.0420.004
call10.000.100.200.181.1619421650.238-0.0280.004
call12.500.001.250.102.0448.000.000.159-0.0380.003
call15.000.000.750.052.4821240.000.109-0.0350.003
call17.500.003.000.072.9534.000.000.096-0.0380.002
call20.000.001.550.393.34031.000.000.088-0.0410.002
call22.500.004.901.453.6705.000.000.082-0.0420.002
call25.000.003.000.007.2490.000.000.352-0.1760.005
call30.000.004.907.204.4334.000.000.072-0.0460.002
call35.000.004.902.004.7832.000.000.069-0.0470.002
call40.000.004.900.055.16631.000.000.066-0.0480.002
put2.500.000.050.044.07211.000.00-0.020-0.0130.001
put5.000.000.050.052.8872450.00-0.071-0.0300.002
put7.500.000.402.501.89131.000.00-0.248-0.0450.004
put10.000.104.903.407.6975.000.00-0.762-0.0260.004
put12.502.506.001.906.0256.000.00-0.841-0.0360.003
put15.005.208.502.206.8161.000.00-0.891-0.0340.003
put17.507.5011.003.007.4310.000.00-0.904-0.0360.002
put20.0010.0013.505.407.9342.000.00-0.912-0.0380.002
put22.5012.5016.000.008.3580.000.00-0.918-0.0400.002
put25.0015.0018.500.008.7240.000.00-0.922-0.0410.002
put30.0020.0023.500.009.3320.000.00-0.928-0.0430.002
put35.0025.0028.500.009.8250.000.00-0.932-0.0440.002
put40.0030.0033.500.0010.2380.000.00-0.935-0.0460.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13D/ASEC
2026-11-058-KCurrent report2026-11-05SEC
2026-11-04424B3SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-10-154Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-10-018-KCurrent report2026-10-01SEC
2026-09-238-KCurrent report2026-09-23SEC
2026-09-158-KCurrent report2026-09-15SEC
2026-09-09424B3SEC
2026-09-098-KCurrent report2026-09-08SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13GSEC
2026-08-06424B3SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-07-308-KCurrent report2026-07-29SEC
2026-07-16SCHEDULE 13GSEC
2026-07-104Statement of changes in beneficial ownership of securities2026-07-08SEC
2026-07-084Statement of changes in beneficial ownership of securities2026-07-07SEC
2026-06-29424B3SEC
2026-06-298-KCurrent report2026-06-29SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-22SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-22SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-22SEC
2026-06-22144Filing for proposed sale of securities under Rule 144.SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-02SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-02SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-02SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-07146.26K200
2026-06001.54M6
2026-0500739.83K2
2026-040000
2026-030000
2026-020000
2026-010000
2025-1217.35K100
2025-110000

Institutional holders

Manager% owned
EQT Fund Management S.a r.l.14.68%
RA CAPITAL MANAGEMENT, L.P.9.70%
PRICE T ROWE ASSOCIATES INC /MD/5.39%
Pivotal bioVenture Partners Investment Advisor LLC5.35%
JPMORGAN CHASE & CO4.31%
RTW INVESTMENTS, LP4.17%
Nan Fung Group Holdings Ltd4.00%
Point72 Asset Management, L.P.3.98%
EVENTIDE ASSET MANAGEMENT, LLC3.36%
Vestal Point Capital, LP2.78%

Funds

Fund% owned
Eventide Healthcare & Life Sciences Fund2.61%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.05%
T. Rowe Price New Horizons Fund, Inc.1.97%
Small Cap Growth Fund1.58%
JPMorgan Small Cap Growth Fund1.54%
T. Rowe Price Health Sciences Fund, Inc.0.96%
iShares Russell 2000 ETF0.92%
Federated Hermes Kaufmann Small Cap Fund0.90%
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund0.72%
JPMorgan Small Cap Blend Fund0.49%

OakChart. EVMN. Cached 15 minutes.